$NBIO News Alert: July 19, 2022 / Nascent Biotech
Post# of 38430
(Total Views: 152)
Posted On: 07/19/2022 8:20:00 AM
$NBIO News Alert: July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"
, a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO" has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab.
A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
The allowed patent application, which is titled, "KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS" (US Patent Application No. 17/515,010), provides broad protection for Pritumumab ("PTB" and the storage conditions related to its use in clinical applications.
Dr. Ivan Babic, in charge of Nascent's R&D, and the inventor listed on the patent, stated, "Allowance of the Pritumumab patent highlights the uniqueness of this naturally-derived antibody and the importance of the right experimental and storage conditions for maintaining its potency."
"This notice of allowance provides further validation of our novel approach to treat brain cancers with Pritumumab, a unique natural antibody capable of crossing the blood brain barrier," said Sean Carrick, CEO of Nascent. "This patent represents a critical step in protecting our technology and establishing Nascent as the leader in treating vimentin-expressing tumors."
A patent from the recently allowed application is pending issuance and is expected to be issued in the near future.
PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy because it targets only cancer cells without damaging healthy cells, unlike chemotherapy.
, a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO" has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
The allowed patent application, which is titled, "KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS" (US Patent Application No. 17/515,010), provides broad protection for Pritumumab ("PTB"
and the storage conditions related to its use in clinical applications. Dr. Ivan Babic, in charge of Nascent's R&D, and the inventor listed on the patent, stated, "Allowance of the Pritumumab patent highlights the uniqueness of this naturally-derived antibody and the importance of the right experimental and storage conditions for maintaining its potency."
"This notice of allowance provides further validation of our novel approach to treat brain cancers with Pritumumab, a unique natural antibody capable of crossing the blood brain barrier," said Sean Carrick, CEO of Nascent. "This patent represents a critical step in protecting our technology and establishing Nascent as the leader in treating vimentin-expressing tumors."
A patent from the recently allowed application is pending issuance and is expected to be issued in the near future.
PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy because it targets only cancer cells without damaging healthy cells, unlike chemotherapy.
(0)
(0)